

27101005177 — COVID-RED

COVID-RED

WP2 – Testing procedure and
implementation

D2.2 Interim report on testing results for SARS-CoV-2 virus

| | |
|---------------------------|------------------------------------------------------|
| Lead contributor | 8. Roche Diagnostics Nederland BV |
| Other contributors | 3. Julius Clinical 6. Sanquin 9. LMZ Dr. Risch |

Document History

| Version | Date | Description |
|---------|------------|-----------------------------------------------------------------|
| V1.0 | 08-10-2021 | Deliverable developed for internal review prior to finalization |
| V1.1 | 26-11-2021 | Table 1 updated after consortium comment |
| V2.0 | 31-05-2022 | Final version |

Abstract

As of 1 June 2020, anyone with respiratory symptoms in the Netherlands can be tested free-of-charge for the SARS-CoV-2 virus. The government aims to provide a test result within 24 hours, and anyone who tests positive is automatically transferred to the public contact-tracing programme.

The COVID-RED project intends to collect information from study participants with a positive signal, who were advised to attend the nearest public testing site, and who are willing to share the result of their test with the study team. This report presents the results of this collection as of November 2021.

Intermediate testing report.

Based on the procedures established in deliverable 2.1 we are providing the following intermediate testing report. Please see in table 1 the current figures and results related to the tests that have been conducted. To cope with vaccinations, antibody testing is being done in part for anti-nucleocapsid antibodies instead/next to anti-spike protein antibodies. Nevertheless, this does not change the basic rationale/approach of the antibody monitoring.

| Table1. Intermediate Testing Report | | | | |
|-------------------------------------|--------------------|-----------------------------------------------------------------------------------|------------------|---------------------------------------------------------------------------------|
| Infections Testing | Number | Positive results | Negative Results | Rejected Samples |
| Participants self reported tests | 9881 | 343 | 9538 | NA |
| Self reported PCR test (0) | 8244 | 304 | 7940 | NA |
| Self reported Antigen tests (1) | 1314 | 29 | 1285 | NA |
| Self reported Serology (2) | 4 | 0 | 4 | NA |
| Self reported unknown (3) | 292 | 8 | 284 | NA |
| Self reported other (88) | 27 | 2 | 25 | NA |
| Participants self tests sent | 718 | | | |
| Participants self tests received | 539 | 0 | 539 | 0 |
| Serology Testing | | | | |
| Baseline samples tested | 2221 (S)/1171 (N)* | | | |
| Learning phase samples tested | 10597 (S)/6326(N)* | 753(non-vacc) and 207(vacc) of which 580 and 86 were seroconversions respectively | | 328 samples (BL+LP) were rejected for analysis due to insufficient blood volume |

* No. of tests. Part of the samples have been tested for both N and S.